川宁生物(301301) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,269,733,317.68, representing a 27.34% increase compared to ¥997,089,543.13 in the same period last year[5] - Net profit attributable to shareholders was ¥174,273,801.35, marking a 74.56% increase from ¥99,834,595.77 year-on-year[5] - Basic and diluted earnings per share increased by 60.00%, from ¥0.05 to ¥0.08[5] - The total operating revenue for Q1 2023 was CNY 1,269,733,317.68, representing an increase of 27.3% compared to CNY 997,089,543.13 in the same period last year[17] - The net profit attributable to the parent company was CNY 175,446,682.72, up 74.4% from CNY 100,595,613.95 in Q1 2022[19] - The total operating costs for Q1 2023 were CNY 1,040,861,350.07, an increase of 18.6% from CNY 876,873,257.88 in the previous year[18] - Research and development expenses amounted to CNY 13,774,801.25, which is a 29.8% increase compared to CNY 10,648,788.15 in Q1 2022[18] - The earnings per share (EPS) for Q1 2023 was CNY 0.08, compared to CNY 0.05 in the same period last year, marking a 60% increase[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,161,408.27, a significant decline of 1,587.75% compared to ¥3,035,553.68 in the previous year[11] - The cash flow from operating activities was CNY 497,255,911.49, a decrease from CNY 552,370,253.53 in the same quarter last year[19] - The total cash outflow from operating activities was CNY 569,522,656.06, an increase of 3.6% from CNY 550,549,856.01 in the previous period[21] - The net cash flow from investing activities was -CNY 4,830,726.92, an improvement from -CNY 10,104,116.74 in the previous period[21] - Cash inflow from financing activities was CNY 1,800,000.00, significantly lower than CNY 286,375,700.00 in the previous period[21] - The total cash outflow from financing activities was CNY 552,167,881.27, an increase from CNY 296,878,751.26 in the previous period[21] - The net cash flow from financing activities was -CNY 550,367,881.27, worsening from -CNY 10,503,051.26 in the previous period[21] - The cash and cash equivalents at the end of the period were CNY 1,023,534,016.97, compared to CNY 489,738,911.25 at the end of the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,114,160,972.62, a decrease of 2.66% from ¥10,390,399,359.24 at the end of the previous year[5] - Accounts receivable increased to ¥1,021,309,437.18 from ¥877,597,384.20, reflecting a growth of about 16.3%[15] - Inventory decreased to ¥1,066,692,446.32 from ¥1,383,634,677.19, indicating a reduction of approximately 23.0%[15] - Current liabilities total ¥2,451,994,634.16, down from ¥2,707,385,477.45, a decrease of approximately 9.4%[16] - Long-term borrowings decreased to ¥1,022,999,996.00 from ¥1,428,000,000.00, a reduction of about 28.4%[16] - The total liabilities decreased to CNY 3,728,227,308.83 from CNY 4,179,912,376.97 at the beginning of the year, reflecting a reduction of 10.7%[17] - The deferred income decreased slightly to CNY 33,177,830.24 from CNY 34,240,935.05 at the beginning of the year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,854[12] - Sichuan Kelun Pharmaceutical holds 70.63% of shares, totaling 1,569,887,643 shares[12] - The total equity attributable to shareholders of the parent company increased to CNY 6,379,931,942.92 from CNY 6,204,485,260.20 at the beginning of the year, reflecting a growth of 2.8%[17] Expenses and Taxation - Management expenses decreased by 47.51% to ¥41,062,024.57 from ¥78,226,671.83 in the same period last year[10] - The company experienced a 90.66% increase in income tax expenses, rising to ¥34,938,429.41 from ¥18,324,953.79[10] - The financial expenses for the quarter were CNY 23,979,158.76, down from CNY 37,145,447.06 in the previous year, indicating a reduction of 35.5%[18] - Tax payments increased to CNY 127,956,669.11 from CNY 35,835,646.80 in the previous period, indicating a substantial rise in tax obligations[20] Other Information - The company plans to expand its agricultural land leasing business, which contributed to the increase in right-of-use assets[9] - The company received government subsidies amounting to ¥2,235,251.24, an increase of 74.45% compared to ¥1,281,281.80 in the previous year[10] - The company reported a significant increase in employee compensation payments, totaling CNY 119,280,108.62, up from CNY 98,469,929.66 in the previous period[20] - The company did not conduct an audit for the first quarter report[21] - The company has a goodwill value of ¥1,365,974.00, unchanged from the previous period[16]